Current issues in pediatric transplantation

Pediatric Transplantation

Volumn 10, Issue 6, 2006, Pages 712-720

  Kelly, D A ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adolescence; Cytomegalovirus; Epstein Barr virus; Immunosuppression; Pediatric liver transplantation

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CHIMERIC ANTIBODY; COSMETIC; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL CONTRACEPTIVE AGENT; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOPTIVE IMMUNOTHERAPY; AMENORRHEA; AUSTRIA; AUTOIMMUNE HEPATITIS; CHRONIC GRAFT REJECTION; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; EPSTEIN BARR VIRUS; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MENORRHAGIA; MORBIDITY; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; SKIN CANCER; STUNTING SYNDROME; SURGICAL MORTALITY; T LYMPHOCYTE; VIRUS INFECTION; VIRUS STRAIN;

ADOLESCENT; BODY IMAGE; CHILD; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSION; MALE; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PREGNANCY; PREGNANCY IN ADOLESCENCE; QUALITY OF LIFE;

EID: 33746895406     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00567.x     Document Type: Conference Paper

References (91)

1. BENFIELD MR, STABLEIN D, TEJANI A. Trends in immunosuppressive therapy: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999: 3: 27-32.
2. KELLY DA. Current results and evolving indications for liver transplantation in children. J Pediatr Gastroenterol Nutr 1998: 27: 214-221.
3. GOSS JA, SHACKLETON CR, MCDIARMID SV, et al. Long-term results of pediatric liver transplantation: An analysis of 569 transplants. Ann Surg 1998: 228: 411-420.
4. SIGFUSSON G, FRICKER FJ, BERNSTEIN D, et al. Long-term survivors of pediatric heart transplantation: A multicenter report of sixty-eight children who have survived longer than five years. J Pediatr 1997: 130: 862-871.
5. BOUCEK MM, FARO A, NOVICK RJ, BENNETT LE, KECK BM, HOSENPUD JD. The Registry of the International Society for Heart and Lung Transplantation: Fourth Official Pediatric Report - 2000. J Heart Lung Transplant 2001: 20: 39-52.
6. BENFIELD MR, MCDONALD R, SULLIVAN EK, STABLEIN DM, TEJANI A. The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999: 3: 152-167.
7. WOLFF G, STRECKER K, VESTER U, LATTA K, EHRICH JH. Non-compliance following renal transplantation in children and adolescents. Pediatr Nephrol 1998: 12: 703-708.
8. KELLY D, JARA P, RODECK B, et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: Randomised European multicentre trial. Lancet 2004: 364: 1054-1061.
9. NEU AM, HO PL, FINE RN, FURTH SL, FIVUSH BA. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study. Pediatr Transplant 2003: 7: 217-222.
10. ARORA-GUPTA N, DAVIES P, MCKIERNAN P, KELLY DA. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004: 8: 145-150.
11. BARTOSH SM, ALONSO EM, WHITINGTON PF. Renal outcomes in pediatric liver transplantation. Clin Transplant 1997: 11: 354-360.
12. MCDIARMID SV. Renal function in pediatric liver transplant patients. Kidney Int Suppl 1996: 53: S77-S84.
13. EVANS HM, MCKIERNAN PJ, KELLY DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005: 79: 1575-1580.
14. LEE WS, GRUNDY R, MILFORD DV, et al. Renal function following liver transplantation for unresectable hepatoblastoma. Pediatr Transplant 2003: 7: 270-276.
15. ARORA N, MCKIERNAN PJ, BEATH SV, DEVILLE DE, GOYET J, KELLY DA. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation. Pediatr Transplant 2002: 6: 214-218.
16. BERG UB, ERICZON BG, NEMETH A. Renal function before and long after liver transplantation in children. Transplantation 2001: 72: 631-637.
17. FILLER G, GELLERMANN J, ZIMMERING M, MAI I. Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. Transpl Int 2000: 13: 201-206.
18. FERRARIS JR, TAMBUTTI ML, REDAL MA, BUSTOS D, RAMIREZ JA, PRIGOSHIN N. Conversion from azathioprine [correction of azathioprina] to mycophenolate mofetil in pediatric renal transplant recipients with chronic rejection. Transplantation 2000: 70: 297-301.
19. AW MM, BROWN NW, ITSUKA T, et al. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003: 9: 383-388.
20. RENZ JF, LIGHTDALE J, MUDGE C, et al. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Liver Transpl Surg 1999: 5: 136-143.
21. DIPCHAND AI, BENSON L, MCCRINDLE BW, COLES J, WEST L. Mycophenolate mofetil in pediatric heart transplant recipients: A single-center experience. Pediatr Transplant 2001: 5: 112-118.
22. KIRKMAN RL. New usage paradigms in antibody therapy: Induction or true prophylaxis? Transplant Proc 1999: 31: 1234-1235.
23. GANSCHOW R, BROERING DC, STUERENBURG I, ROGIERS X, HELLWEGE HH, BURDELSKI M. First experience with basiliximab in pediatric liver graft recipients. Pediatr Transplant 2001: 5: 353-358.
24. VESTER U, KRANZ B, TESTA G, et al. Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients. Pediatr Transplant 2001: 5: 297-301.
25. KAHAN BD, PODBIELSKI J, NAPOLI KL, KATZ SM, MEIER-KRIESCHE HU, VAN BUREN CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998: 66: 1040-1046.
26. CASAS-MELLEY AT, FALKENSTEIN KP, FLYNN LM, ZIEGLER VL, DUNN SP. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr Transplant 2004: 8: 362-366.
27. MAHADEVAN SBK, BEATH SV, DAVIDS P, et al. Safety and efficacy of Sirolimus in children following chronic rejection and/or nephrotoxicity post intestinal transplant (Itx) and liver transplantation (LTx). J Ped Gasro Nutr 2004: 39: S152.
28. THORP M, DEMATTOS A, BENNETT W, BARRY J, NORMAN D. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000: 69: 1218-1220.
29. PENSON MG, WINTER WE, FRICKER FJ, et al. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. J Heart Lung Transplant 1999: 18: 707-713.
30. SWENSON JM, FRICKER FJ, ARMITAGE JM. Immunosuppression switch in pediatric heart transplant recipients: Cyclosporine to FK 506. J Am Coll Cardiol 1995: 25: 1183-1188.
31. MCALISTER VC, PELTEKIAN KM, MALATJALIAN DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001: 7: 701-708.
32. PEREZ FONTAN M, RODRIGUEZ-CARMONA A, GARCIA FALCON T, FERNANDEZ RIVERA C, VALDES F. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999: 33: 21-28.
33. SAGEDAL S, NORDAL KP, HARTMANN A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000: 70: 1166-1174.
34. PAYA CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999: 1(Suppl. 1): 8-12.
35. HJELMESAETH J, SAGEDAL S, HARTMANN A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004: 47: 1550-1556.
36. MANEZ R, BREINIG MC, LINDEN P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalo-virus disease. J Infect Dis 1997: 176: 1462-1467.
37. SMETS F, BODEUS M, GOUBAU P, et al. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients. J Hepatol 2000: 32: 100-104.
38. GUTHERY SL, HEUBI JE, BUCUVALAS JC, et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003: 75: 987-993.
39. NEWELL KA, ALONSO EM, WHITINGTON PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996: 62: 370-375.
40. REYES J, JAIN A, MAZARIEGOS G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000: 69: 2573-2580.
41. SRIVASTAVA T, ZWICK DL, ROTHBERG PG, WARADY BA. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999: 13: 748-754.
42. FATIO R, SUTSCH G, MAYER K, et al. Posttransplant lymphoproliferative disorders in cardiac transplant patients. Transplant Proc 1998: 30: 1118-1120.
43. COX KL, LAWRENCE-MIYASAKI LS, GARCIA-KENNEDY R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995: 59: 524-529.
44. SMETS F, SOKAL EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: Role of immunity, diagnosis, and management. Pediatr Transplant 2002: 6: 280-287.
45. HAQUE T, WILKIE GM, TAYLOR C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002: 360: 436-442.
46. HAAGSMA EB, HAGENS VE, SCHAAPVELD M, et al. Increased cancer risk after liver transplantation: A population-based study. J Hepatol 2001: 34: 84-91.
47. BOUWES BAVINCK JN, HARDIE DR, GREEN A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996: 61: 715-721.
48. KEHINDE EO, PETERMANN A, MORGAN JD, et al. Triple therapy and incidence of de novo cancer in renal transplant recipients. Br J Surg 1994: 81: 985-986.
49. KOVACH BT, SAMS HH, STASKO T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant 2005: 19: 726-734.
50. KELLY DA. Nutritional factors affecting growth before and after liver transplantation. Pediatr Transplant 1997: 1: 80-84.
51. RODECK B, MELTER M, HOYER PF, RINGE B, BRODEHL J. Growth in long-term survivors after orthotopic liver transplantation in childhood. Transplant Proc 1994: 26: 165-166.
52. DUNN SP, FALKENSTEIN K, LAWRENCE JP, et al. Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients. Transplantation 1994: 57: 544-547.
53. KELLY DA. Posttransplant growth failure in children. Liver Transpl Surg 1997: 3: S32-S39.
54. ELLIS D. Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants. Pediatr Nephrol 2000: 14: 689-694.
55. CHAKRABARTI P, WONG HY, SCANTLEBURY VP, et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 2000: 70: 760-764.
56. REDING R, GRAS J, SOKAL E, OTTE JB, DAVIES HF. Steroid-free liver transplantation in children. Lancet 2003: 362: 2068-2070.
57. GANSCHOW R, MELTER M, WALLOT M, et al. Maintained efficacy with steroid minimization after pediatric liver transplantation with Basiliximab (Simulect®) induction therapy: A multicenter randomized 12-month trial. International Pediatric Transplantation Association. Austria: Innsbruck, 2005: 9: 178.
58. KERKAR N, HADZIC N, DAVIES ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998: 351: 409-413.
59. ANDRIES S, CASAMAYOU L, SEMPOUX C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: Incidence and maintenance therapy with azathioprine. Transplantation 2001: 72: 267-272.
60. EVANS HM, KELLY DA, MCKIERNAN PJ, HUBSCHER S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006: 43: 1109-1117.
61. MIYAGAWA-HAYASHINO A, HAGA H, SAKURAI T, SHIRASE T, MANABE T, EGAWA H. De novo autoimmune hepatitis affecting allograft but not the native liver in auxiliary partial orthotopic liver transplantation. Transplantation 2003: 76: 271-272.
62. BOGDANOS DP, CHOUDHURI K, VERGANI D. Molecular mimicry and autoimmune liver disease: Virtuous intentions, malign consequences. Liver 2001: 21: 225-232.
63. BUCY RP, XU XY, LI J, HUANG G. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993: 151: 1039-1050.
64. SALCEDO M, VAQUERO J, BANARES R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002: 35: 349-356.
65. VERGANI D, MIELI-VERGANI G. Autoimmunity after liver transplantation. Hepatology 2002: 36: 271-276.
66. CHARDOT C, NICOLUZZI JE, JANSSEN M, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001: 71: 224-229.
67. BEATH SV, BROOK GD, KELLY DA, et al. Successful liver transplantation in babies under 1 year. BMJ 1993: 307: 825-828.
68. WAYMAN KI, COX KL, ESQUIVEL CO. Neurodevelopmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation. J Pediatr 1997: 131: 894-898.
69. VAN MOURIK ID, BEATH SV, BROOK GA, et al. Long-term nutritional and neurodevelopmental outcome of liver transplantation in infants aged less than 12 months. J Pediatr Gastroenterol Nutr 2000: 30: 269-275.
70. ALONSO EM, NEIGHBORS K, MATTSON C, et al. Functional outcomes of pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2003: 37: 155-160.
71. BUCUVALAS JC, BRITTO M, KRUG S, et al. Health-related quality of life in pediatric liver transplant recipients: A single-center study. Liver Transpl 2003: 9: 62-71.
72. KRULL K, FUCHS C, YURK H, BOONE P, ALONSO E. Neuro-cognitive outcome in pediatric liver transplant recipients. Pediatr Transplant 2003: 7: 111-118.
73. QVIST E, PIHKO H, FAGERUDD P, et al. Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood. Pediatr Transplant 2002: 6: 53-62.
74. VINER R, KEANE M. Youth Matters: Evidence-Based Practice for the Care of Young People in Hospital. London, Action for Sick Children, 1998.
75. MCKINNEY JP, FITZGERALD HE, STROMMEN EA. The Adolescent and Young Adult. Illinois: Dorsey Press, 1977.
76. CODONER-FRANCH P, BERNARD O, ALVAREZ F. Long-term follow-up of growth in height after successful liver transplantation. J Pediatr 1994: 124: 368-373.
77. JAIN A, VENKATARAMANAN R, FUNG JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997: 64: 559-565.
78. NILES DG, RYNEARSON RD, BAUM M, NEUFELD RD, CARUSO JM. A study of craniofacial growth in infant heart transplant recipients receiving cyclosporine. J Heart Lung Transplant 2000: 19: 231-239.
79. SUDAN DL, SHAW BWJR, LANGNAS AN. Causes of late mortality in pediatric liver transplant recipients. Ann Surg 1998: 227: 289-295.
80. WATSON AR. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol 2000: 14: 469-472.
81. FALKENSTEIN K, FLYNN L, KIRKPATRICK B, CASA-MELLEY A, DUNN S. Non-compliance in children post-liver transplant. Who are the culprits? Pediatr Transplant 2004: 8: 233-236.
82. MCDONAGH JE, KELLY DA. Transitioning care of the pediatric recipient to adult caregivers. xi-xii. Pediatr Clin North Am 2003: 50: 1561-1583.
83. CUNDY TF, O'GRADY JG, WILLIAMS R. Recovery of menstruation and pregnancy after liver transplantation. Gut 1990: 31: 337-338.
84. FRASER FC, SAJOO A. Teratogenic potential of corticosteroids in humans. Teratology 1995: 51: 45-46.
85. ARMENTI VT, MORITZ MJ, DAVISON JM. Drug safety issues in pregnancy following transplantation and immunosuppression: Effects and outcomes. Drug Saf 1998: 19: 219-232.
86. HOU S. Pregnancy in chronic renal insufficiency and end-stage renal disease. Am J Kidney Dis 1999: 33: 235-252.
87. CASELE HL, LAIFER SA. Pregnancy after liver transplantation. Semin Perinatol 1998: 22: 149-155.
88. RAMOS HC, REYES J, ABU-ELMAGD K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995: 59: 212-217.
89. REYES J, ZEEVI A, RAMOS H, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993: 25: 3315-3319.
90. RIORDAN SM, WILLIAMS R. Tolerance after liver transplantation: Does it exist and can immunosuppression be withdrawn? J Hepatol 1999: 31: 1106-1119.
91. DEVLIN J, DOHERTY D, THOMSON L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998: 27: 926-933.